• JHU-083: Separating Glutamate and Redox Biology

  2026-09-25

  JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor for investigating glutaminase activity and glutamate biology in experimental cerebral malaria research. This article explains how to distinguish its neurological model applications from new findings on GSTA1-driven glutathione depletion—and why those pathways should not be conflated.

• SERCA2 Dysfunction Drives Pulmonary Vascular Remodeling

  2026-09-25

  The study links SERCA2 dysfunction in pulmonary artery smooth muscle cells to reduced PPARγ/PGC1α/Nrf2 signaling, oxidative stress, inflammation, and pulmonary vascular remodeling. Its intervention results support this pathway as a mechanistic framework for further research, while leaving important questions about model specificity and clinical transferability unresolved.

• Vemurafenib Workflows for Melanoma Resistance

  2026-09-24

  Use Vemurafenib (PLX4032) to connect BRAF V600-mutant target engagement with cell-growth and resistance readouts. This workflow pairs genotype-aware dosing with early signaling measurements and multi-omics-informed controls, helping distinguish pathway suppression from adaptive rebound.

• Palomid 529 (P529) in ESCC Pathway Research

  2026-09-24

  Use Palomid 529 (P529) to test how blocking both mTOR complexes affects PI3K/Akt/mTOR pathway output, tumor-cell phenotypes, and endothelial responses. This workflow pairs pharmacology with genetic tests of the RCN2–UBR5–PPP2CA axis, while keeping pathway engagement distinct from proof of cisplatin or radiation sensitization.

• Chrysin Limits Dry Eye via Ferroptosis and Inflammation

  2026-09-23

  A 2026 study links NOX2-driven oxidative stress and STING/NLRP3 inflammatory signaling to corneal epithelial injury in dry eye, and reports that chrysin suppresses both pathways in experimental models. The findings provide mechanistic support for chrysin as a preclinical research candidate while leaving clinical efficacy, dosing, and pathway specificity to be established.

• Rimonabant as a Receptor-Resolution Tool

  2026-09-23

  Rimonabant (SR141716) provides a rigorous way to test whether cannabinoid-related phenotypes depend on CB1 signaling. This article connects CB1 pharmacology with terpene analgesia research and translates receptor attribution into practical assay decisions.

• Praeruptorin A Experimental Workflows

  2026-09-22

  Build reproducible Praeruptorin A studies around orthogonal readouts for inflammation, ferroptosis, cardiomyopathy research, and metastatic behavior. This workflow-focused guide connects concentration design, pathway validation, and troubleshooting to practical bench decisions.

• From Hypoxia to Viability: Smarter GBM Models

  2026-09-22

  High-cell-density glioblastoma models can reproduce hypoxia-linked therapy resistance, but translational confidence depends on measuring both mechanism and cell-state outcomes. This thought-leadership guide explains how Calcein-AM Propidium Iodide staining can add a practical viability layer to engineered tumor models without confusing membrane integrity with complete biological function.

• Cy3 TSA Fluorescence System Kit for Spatial Assays

  2026-09-21

  The Cy3 TSA Fluorescence System Kit strengthens IHC, ICC, and HRP-compatible ISH when conventional fluorescence is too dim to resolve rare targets. This guide translates proximity-proteomics findings into practical staining workflows, controls, optimization experiments, and spatial validation strategies.

• H 89 2HCl: PKA Control in Neuronal Calcium Signaling

  2026-09-21

  H 89 2HCl is more than a routine PKA inhibitor: used with cAMP, phosphorylation, membrane-trafficking, and calcium readouts, it can help translational researchers test how kinase activity connects glucocorticoid signaling to Kv2.1 and CaV1.2 regulation.

• Partial BACE1 Inhibition and Synaptic Function

  2026-09-20

  Satir et al. tested whether moderate β-secretase inhibition could lower amyloid-β secretion without disrupting neuronal communication. In primary rat cortical cultures, reductions below 50% preserved synaptic transmission, whereas stronger inhibition reduced both amyloid-β release and synaptic activity, supporting exposure-sensitive strategies for Alzheimer’s disease research.

• One-step TUNEL Cy5 Apoptosis Detection Kit

  2026-09-19

  Learn how SKU K1135 supports interpretable DNA-fragmentation measurements across cultured cells and tissue sections. This scenario-based guide covers assay selection, protocol controls, spectral settings, interpretation, and practical vendor evaluation for apoptosis research.

• GDC-0941: Reliable PI3K/Akt Assays

  2026-09-18

  Learn how GDC-0941 (SKU A8210) can improve interpretation of cell viability, proliferation, pathway, and apoptosis assays through controlled PI3K/Akt inhibition. This scenario-based guide covers dosing, solvent handling, endpoint selection, data interpretation, and practical supplier evaluation.

• PD 0332991: Practical CDK4/6 Assay Workflows

  2026-09-18

  Build more informative cancer assays with PD 0332991 by separating reversible growth arrest from true cell killing. This workflow combines Rb-pathway validation, time-resolved cell-cycle analysis, and orthogonal viability measurements for stronger breast cancer and tumor-response studies.

• GSTA1, Glutathione Loss, and α-Amanitin Hepatotoxicity

  2026-09-17

  A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin liver injury rather than solely a protective detoxification enzyme. By combining multi-omics, protein-interaction assays, animal pathology, and genetic perturbation, the work links NRF2-associated GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte damage.

8604 records 4/574 page Previous Next 12345 下5页 Last page